14 results on '"Rizvi, H."'
Search Results
2. COVID-19 in patients with lung cancer
3. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
4. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
5. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
6. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
7. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
8. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
9. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
10. 1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
11. Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
12. LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
13. 1407P - Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
14. 1311P - LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.